• Adaptive Pathways – An Imperative for Change

    In today’s blog post we talk to Mark H Mayer, Senior Advisor–Global Regulatory Policy and Intelligence, Eli Lilly and Company. What’s an adaptive pathway?  “Adapt or perish” is a quote generally a…

  • The Difference between Cost-effectiveness and Affordability

    Today’s guest post comes from Lauren Fischer, Vice President, Corporate Affairs at Lilly Canada. Who sets the price of a patented medicine in Canada? Whose role is it to assess whether it’s affordable…

  • Research Isn’t Just Science

    Editor's Note: This post is guest authored by Jennifer Byrne, founder of the nonprofit organization Greater Gift and former CEO of PMG Research, Inc. Jennifer is highly committed to building better b…

  • How Art Can Spark a Movement in Clinical Research Awareness

    Lilly's Hero's Journey (TM) Art project demonstrates the power of art in bringing people together and truly sparking a movement. In this instance, it is a movement towards celebrating clinical trial p…

  • Taking a Closer Look at Access to New Medicines

    Today’s guest post comes from Lauren Fischer, Vice President, Corporate Affairs at Lilly Canada. The sustainability of Canada’s healthcare system is being tested. Demands on the system increase with e…